The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
Danish dermatology specialist LEO Pharma recently announced that its anti-interleukin-13 (IL-13) biologic therapy tralokinumab, which is in development for the treatment of moderate-to-severe atopic dermatitis, met all its primary and secondary endpoints across three pivotal Phase III studies as part of the company’s ECZTRA trial series. 23 December 2019
Danish dermatology specialist LEO Pharma says that tralokinumab – an investigational, fully-human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase III studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. 12 December 2019
Spain’s leading drugmaker Almirall has announced the publication of long-term safety data from a 40-week, Phase III open-label extension study of Seysara (sarecycline) in patients nine years of age and older. 11 December 2019
Shares of Solasia Pharma shot up 33.3% to 200 yen by close of trading today, after revealing that it has entered into an exclusive license agreement with fellow Japan-based Maruho for commercialization of Solasia’s product SP-04 (PledOx). 11 December 2019
French pharma major Sanofi was trading 5% higher as Tuesday’s activity entered its final hour, after the company announced a new strategy. 10 December 2019
Texas, USA-based XBiotech revealed on Saturday that it has entered into a definitive agreement with Janssen Biotech, part of US healthcare giant Johnson & Johnson, to sell its novel antibody, bermekimab, that neutralizes interleukin-1 alpha (IL-1⍺). IL-1⍺ promotes disease-causing inflammation in a wide range of medical conditions. 7 December 2019
Shares in Belgian drugmaker UCB were set to close 2% up on Friday following the presentation of data on the company’s key pipeline asset, bimekizumab. 6 December 2019
In recent years, digital transformation has gone from being a promise to a reality, writes Francesca Domenech Wuttke, Chief Digital Officer, Almirall. 2 December 2019
The Australian subsidiary of AbbVie has announced the federal government’s decision to list Skyrizi (risankizumab), a new treatment option for adults living with severe chronic plaque psoriasis, which eligible Australian patients will be able to access from December 1, 2019 on the Pharmaceutical Benefits Scheme (PBS). 2 December 2019
Given that they have a certain luxury for blue sky thinking and the capacity to lead rather than react to industry and societal trends, for big pharma companies to have highly ambitious digital strategies is not unusual. 28 November 2019
Japan-based Chugai Pharmaceutical has decided to pull out of the Korean joint venture with South Korea’s JW Pharmaceutical that was established on a 50%/50% basis in 1992. 27 November 2019
Privately-held Danish company MC2 Therapeutics today announced that the US Food and Drug Administration has accepted for review its New Drug Application (NDA) for Wynzora Cream (calcipotriene and betamethasone dipropionate; previously dubbed MC2-01 Cream). 21 November 2019
Weeks after presenting positive Phase III trial results on the company’s key pipeline candidate, bimekizumab, UCB has proven that the first study was no fluke. 15 November 2019
Danish dermatology specialist Leo Pharma has exercised an option in its collaboration with HitGen, a Chinese company with an early-stage drug discovery platform based on DNA encoded chemical libraries (DELs). 13 November 2019
Privately-held German group Merz has announced plans to reorganize into three independently operating businesses focusing on medical aesthetics, therapeutics and consumer care. 13 November 2019
Spanish drugmaker Almirall has sustained the growth with its most recent financial results that has characterized the company’s turnaround since 2017. 11 November 2019
Shares in AnaptysBio fell over 70% on Friday, after the firm announced disappointing top-line data from its ATLAS trial, a Phase IIb study of etokimab in moderate-to-severe atopic dermatitis. 11 November 2019
Third-quarter 2019 sales for US biotech Celgene came in at $4.52 billion, up 16% year-on-year and beating consensus forecasts of $4.41 billion. 1 November 2019